Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 1:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1Phase 2 Interventional Results available

Effect of Intranasal Insulin on LH Concentrations in Man

NCT02154477
Conditions
Hypogonadotropic Hypogonadism
Interventions
intranasal insulin, placebo (intranasal saline)
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Odessa, Texas
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Memory and Insulin in Early Alzheimer's Disease

NCT00581867
Conditions
Alzheimer's Disease
Interventions
Insulin Aspart, Placebo
Drug
Lead sponsor
Jeff Burns, MD
Other
Eligibility
60 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Regular Insulin, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
55 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Saline, Insulin detemir, Insulin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 89 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Tacoma, Washington
Conditions
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Insulin (Humulin® R U-100), Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 85 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Irvine, California • New Haven, Connecticut + 18 more
Withdrawn Phase 1Phase 2 Interventional

Post Operative Delirium Study

NCT04635774
Conditions
Delirium
Interventions
Insulin, Saline
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Type 2 Diabetes, Insulin Sensitivity/Resistance, Cognition, Brain Blood Flow
Interventions
Intranasal Insulin, Intranasal Placebo, High Intensity Exercise
Drug · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
55 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
New Brunswick, New Jersey • Piscataway, New Jersey
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Memory Aid by Intranasal Insulin in Diabetes (MemAID)

NCT02415556
Conditions
Type 2 Diabetes Mellitus
Interventions
Regular Human Insulin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
289 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Terminated Phase 1Phase 2 Interventional Results available

Intranasal Insulin for the Treatment of HAND

NCT03081117
Conditions
HIV Dementia, HIV-Associated Cognitive Motor Complex
Interventions
Insulin, intranasal, Placebo, intranasal
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 69 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Spinal Cord Injury
Interventions
Regular Insulin, 0.9 % Normal Saline
Drug · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Saint Paul, Minnesota
Completed Phase 2 Interventional Results available

Cardiac Surgery Neuroprotection Study in Elders

NCT01561378
Conditions
Post-operative Cognitive Decline, Post-operative Delirium
Interventions
Aspart insulin, Normal saline, Intranasal mucosal atomizer device
Drug · Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
65 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Parkinson Disease, Multiple System Atrophy
Interventions
Intranasal Insulin
Drug
Lead sponsor
Peter Novak
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Alzheimer Disease
Interventions
Empagliflozin, Insulin, Insulin Placebo, Empagliflozin Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Alcohol Use Disorder
Interventions
Regular Human Insulin then Placebo, Placebo then Regular Human Insulin
Drug
Lead sponsor
Brown University
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes

NCT01206322
Conditions
Type 2 Diabetes Mellitus
Interventions
Intranasal insulin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Healthy, Vasodilation, Insulin Resistance, Autonomic Dysfunction, Obesity
Interventions
Carbon dioxide breathing, Neurovascular Coupling, Human insulin
Other · Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 45 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Conditions
Type 1 Diabetes
Interventions
Insulin, Insulin LISPRO
Drug
Lead sponsor
Hompesch, Marcus, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chula Vista, California
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Intranasal Insulin in Frontotemporal Dementia (FTD)

NCT04115384
Conditions
Frontotemporal Dementia, Behavioral Variant
Interventions
Novolin-R insulin
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
41 Years to 89 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
Down Syndrome
Interventions
Insulin glulisine, Saline
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
35 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
Schizophrenia
Interventions
Insulin or Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Psychosis, Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
Interventions
Intranasal Insulin
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Mild Cognitive Impairment, Alzheimer's Disease (AD)
Interventions
Insulin glulisine, Placebo
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
50 Years to 90 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Conditions
Stroke
Interventions
Intranasal Insulin, Intranasal saline
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise

NCT04292535
Conditions
Insulin, Exercise
Interventions
Placebo into the intranasal mucosa, 20 IU NovoLog Insulin aspart into the intranasal mucosa, 40 IU NovoLog Insulin aspart into the intranasal mucosa, 60 IU NovoLog Insulin aspart into the intranasal mucosa, 80 IU NovoLog Insulin aspart into the intranasal mucosa, 100 IU NovoLog Insulin aspart into the intranasal mucosa, 120 IU NovoLog Insulin aspart into the intranasal mucosa
Drug
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
East Lansing, Michigan